Astek Diagnostics names Doug White executive chairman

Astek Diagnostics has appointed diagnostics veteran Doug White as executive chairman as the company pushes its Jiddu rapid UTI platform toward FDA submission and commercial launch. The move adds senior leadership and governance experience at a critical stage for the Baltimore-based company.

Why it matters: - Astek Diagnostics is adding a seasoned diagnostics operator at a point when leadership, capital formation and partnerships could shape whether Jiddu reaches market on schedule. - Jiddu is designed to shorten urinary tract infection diagnosis from days to about one hour, which could affect treatment decisions and antibiotic use.

What happened: - Astek Diagnostics appointed Doug White executive chairman of its board of directors on September 21, 2026. - White will work closely with founder and CEO Mustafa Al-Adhami. - White will focus on governance, capital formation and strategic partnerships. - White said he is excited to work with the board, investors and Al-Adhami as Astek accelerates development and commercialization of a system intended to improve the standard of care for UTI diagnosis and treatment.

The details: - White joined Astek as a strategic consultant in March 2026. - Astek says White quickly became a central force in shaping the company’s financing strategy, commercial model and operational capabilities. - Al-Adhami said White has already helped sharpen how the company thinks, plans and executes. - Astek said White has scaled diagnostics businesses in markets the company is entering. - Valentina Milanova, managing director, said White’s leadership and industry experience have already had a transformative impact on the company’s strategy and execution. - White has more than 30 years of commercial and operational leadership experience in diagnostics and medical devices. - White has held executive roles at Digene, Qiagen, BD Diagnostics, Bayer Diagnostics, PolyMedco and Emergent BioSolutions. - White helped build the commercial engine behind HPV-based cervical cancer screening in the U.S. - White also helped scale Emergent’s Devices Business Unit tenfold, including the acquisition and expansion of Narcan Nasal Spray. - Astek’s Jiddu platform is designed to confirm bacterial infection and deliver antibiotic susceptibility results in roughly one hour. - The platform uses a benchtop fluorometric analyzer and single-use microfluidic cartridges. - Astek says the system aims to replace the one- to three-day wait tied to traditional urine culture. - Astek is based in Baltimore. - The company did not disclose financial terms of White’s appointment.

Between the lines: - The appointment signals that Astek is moving from product development toward the harder business phases of regulatory review, commercialization and market entry. - Hiring an executive chairman with deep diagnostics experience can help build credibility with investors, partners and future customers.

What's next: - Astek plans to continue advancing Jiddu toward FDA submission and commercial launch. - White is expected to support board leadership while helping guide the company’s financing and partnership strategy. - Astek will likely continue building the board around the effort to bring Jiddu to market.

The bottom line: - Astek is betting that experienced governance and commercial leadership will help turn Jiddu from a promising diagnostic platform into a marketable product.